264 related articles for article (PubMed ID: 37768506)
1. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs.
Gianesini S; De Luca L; Feodor T; Taha W; Bozkurt K; Lurie F
Adv Ther; 2023 Dec; 40(12):5137-5154. PubMed ID: 37768506
[TBL] [Abstract][Full Text] [Related]
2. VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
Mezalek ZT; Feodor T; Chernukha L; Chen Z; Rueda A; Sánchez IE; Ochoa AJG; Chirol J; Blanc-Guillemaud V; Lohier-Durel C; Ulloa JH
Adv Ther; 2023 Nov; 40(11):5016-5036. PubMed ID: 37728696
[TBL] [Abstract][Full Text] [Related]
3. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting.
Bogachev V; Boldin B; Turkin P; Samenkov A; Dzhenina O
Future Cardiol; 2022 Sep; 18(10):777-785. PubMed ID: 36004765
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
Kakkos SK; Nicolaides AN
Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
[TBL] [Abstract][Full Text] [Related]
5. New Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness.
Bouskela E; Lugli M; Nicolaides A
Adv Ther; 2022 Oct; 39(10):4413-4422. PubMed ID: 35951224
[TBL] [Abstract][Full Text] [Related]
6. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease.
Nicolaides AN
Adv Ther; 2020 Feb; 37(Suppl 1):1-5. PubMed ID: 31970659
[TBL] [Abstract][Full Text] [Related]
7. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
Ulloa JH
Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
[TBL] [Abstract][Full Text] [Related]
9. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
[TBL] [Abstract][Full Text] [Related]
10. Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life.
Lurie F; Branisteanu DE
Clin Drug Investig; 2023 Jun; 43(Suppl 1):9-13. PubMed ID: 37171748
[TBL] [Abstract][Full Text] [Related]
11. Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease.
Ulloa JH; Lurie F; Santiago FR; Gianesini S; Reina L; Wang J; Jindal R; Taha W; Bokuchava M; Mansilha A
Int Angiol; 2023 Dec; 42(6):465-476. PubMed ID: 38015554
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy.
Mansilha A; Sousa J
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29874834
[TBL] [Abstract][Full Text] [Related]
13. Early Stages of Chronic Venous Disease: Medical Treatment Alone or in Addition to Endovenous Treatments.
Mansilha A
Adv Ther; 2020 Feb; 37(Suppl 1):13-18. PubMed ID: 31981108
[TBL] [Abstract][Full Text] [Related]
14. The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence.
Davies AH
Adv Ther; 2019 Mar; 36(Suppl 1):5-12. PubMed ID: 30758738
[TBL] [Abstract][Full Text] [Related]
15. The Most Severe Stage of Chronic Venous Disease: An Update on the Management of Patients with Venous Leg Ulcers.
Nicolaides AN
Adv Ther; 2020 Feb; 37(Suppl 1):19-24. PubMed ID: 31970660
[TBL] [Abstract][Full Text] [Related]
16. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
Jantet G
Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of micronized purified flavonoid fraction in treatment of chronic venous oedema].
Bogachev VI; Boldin BV; Turkin PI; Samenkov AI
Angiol Sosud Khir; 2020; 26(2):86-94. PubMed ID: 32597888
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Olszewski W
Angiology; 2000 Jan; 51(1):25-9. PubMed ID: 10667640
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease.
Kirienko A; Radak D; Maggioli A
Curr Med Res Opin; 2019 Mar; 35(3):553-557. PubMed ID: 29992831
[TBL] [Abstract][Full Text] [Related]
20. Advanced Stages of Chronic Venous Disease: Evolution of Surgical Techniques and Advantages of Associated Medical Treatment.
Lurie F
Adv Ther; 2020 Feb; 37(Suppl 1):6-12. PubMed ID: 31981107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
